HelpDesk answers: is it safe to add long-acting β-2 agonists to inhaled corticosteroids in patients with persistent asthma?

Laurie Townsend, Diane J Madlon-Kay

Research output: Contribution to journalArticlepeer-review

Abstract

Possibly. Long-acting β-2 agonists (LABAs) used in combination with inhaled corticosteroids (ICS) don't appear to increase all-cause mortality or serious adverse events in patients with persistent asthma compared with ICS alone. Studies showing an increase in catastrophic events had serious methodologic issues. A large surveillance study is ongoing.

Original languageEnglish (US)
Pages (from-to)370-371
Number of pages2
JournalThe Journal of family practice
Volume64
Issue number6
StatePublished - Jun 1 2015

Fingerprint Dive into the research topics of 'HelpDesk answers: is it safe to add long-acting β-2 agonists to inhaled corticosteroids in patients with persistent asthma?'. Together they form a unique fingerprint.

Cite this